[go: up one dir, main page]

WO2011161465A2 - Composition pour le traitement de la peau - Google Patents

Composition pour le traitement de la peau Download PDF

Info

Publication number
WO2011161465A2
WO2011161465A2 PCT/GB2011/051191 GB2011051191W WO2011161465A2 WO 2011161465 A2 WO2011161465 A2 WO 2011161465A2 GB 2011051191 W GB2011051191 W GB 2011051191W WO 2011161465 A2 WO2011161465 A2 WO 2011161465A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
oil
acid
skin
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2011/051191
Other languages
English (en)
Other versions
WO2011161465A3 (fr
Inventor
Keith Coupland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEEDS GROUP LP
Original Assignee
SEEDS GROUP LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SEEDS GROUP LP filed Critical SEEDS GROUP LP
Publication of WO2011161465A2 publication Critical patent/WO2011161465A2/fr
Publication of WO2011161465A3 publication Critical patent/WO2011161465A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]

Definitions

  • the present application relates to a composition for use in the stimulation of sirtuin synthesis in skin cells.
  • SIRT 1 is a member of the gene family (sirtuins) that are nicotinamide adenine dinucleotide ( AD) + dependent deacetylases.
  • Sirtuins are enzymes that deacetylate proteins notably histones conferring DNA stability and prolonging life in many organisms ranging from yeast to mammals.
  • SIRT 1 is expressed in human skin fibroblasts and is down-regulated by UV radiation and reactive oxygen species (see Cao,C, et al (2008) "SIRT 1 confers protection against UVB and H2O2 induced cell death via modulation of p53 and ⁇ in cultured skin keratinocytes", J Cell Mol Med 13(9b) 3632-3643).
  • the SIRT 1 activator resveratrol is both an antioxidant and inhibitor of UV initiated skin damage.
  • Resveratrol has been promoted as an ingredient in skin-care products and "sirtuin - activation technology" is a key area of research for many cosmetic companies (see Moreau, M., et al (2007) “Enhancing cell longevity for cosmetic applications: a complimentary approach", J Drugs Dermatol June 6(6 Suppl) 14-19).
  • composition comprising: (i) stearidonic acid, or an ester thereof, and optionally (ii) conjugated octadecatrienoic acid or an ester thereof for use in the stimulation of sirtuin synthesis in skin cells.
  • component (i) is a stearidonic acid, or an ester thereof such as echium oil and component (ii) is a conjugated octadecatrienoic acid or an ester thereof such as calendula oil.
  • this preferred active ingredient is calendula oil and not calendula extract.
  • the extract is a decoction of calendula flowers (usually in a vegetable oil such as sunflower seed oil or peanut oil) whereas the oil may be produced by grinding up the seeds of the Calendula plant and extracting the diminuted seed with a suitable solvent such as hexane or super critical carbon dioxide. Alternatively the oil may be obtained by simply cold pressing the Calendula seeds. Calendula extract does not contain calendic acid whereas calendula oil does.
  • Most plant seed oils are triglyceride esters of fatty acids and glycerol.
  • the fatty acids may be saturated, mono-unsaturated or poly-unsaturated.
  • the plant seed oils that are of value in the treatment of skin conditions, by stimulating collagen production in skin cells are those containing poly-unsaturated fatty acids.
  • Fatty acids are aliphatic monocarboxylic acids which occur naturally in animal or vegetable fats or oils in the form of esters particularly triglyceride esters. Because of their perceived usefulness in for example human nutrition, a great deal of effort has been put into extracting triglyceride esters containing poly-unsaturated fatty acids from their natural sources.
  • Stearidonic acid is a polyunsaturated fatty acid of the n3 family which is described in the conventional nomenclature as CI 8:4n3. It can be found in the form of a triester of glycerol (or triglyceride) in the oils of blackcurrant, redcurrant and gooseberry pips.
  • WO 97/46220 discloses that SDA triglyceride can be sourced from oil extracted from the seeds of the Boraginaceae plant family and that the oil itself can be used in dietetic, cosmetic and healthcare products, without the need for additional treatment or purification.
  • a particularly rich source of SDA is the seeds of the genus Echium.
  • compositions of the present invention may also comprise a physiologically acceptable carrier.
  • a physiologically acceptable carrier may additionally comprise one or more of a moisturiser, an emollient, an emulsifier, a preservative, a dispersant, a viscosity modifier, a herbal extract, a solvent, a chelating agent, an antioxidant, vitamin C, an ester of vitamin C, ascorbyl palmitate, magnesium ascorbyl phosphate, a water-proofing agent, a pH adjuster, a perfume, and an aminoacid, peptide or protein.
  • compositions may be formulated as solids, liquids, aerosols, creams, emulsions, gels or in capsule form.
  • composition comprising stearidonic acid (or an ester thereof) derived for example from Echium oil, and an additional lipid (derived for example from calendula oil) which enhances the procollagen effects of stearidonic acid.
  • stearidonic acid or an ester thereof
  • additional lipid derived for example from calendula oil
  • Figure 1 is a diagram showing the EST- 1000 epidermis model
  • Figure 2 is a bar graph showing the effect of the various cosmetic products on sirtuin gene expression
  • Figure 3 is a bar graph showing the effect of the composition in accordance with the invention on sirtuin gene expression.
  • Figure 4 is a bar graph showing the effect of various different oil types on sirtuin gene expression.
  • Cream Lipid A of Lotions 789 and 790 was echium oil and the synergist oil of Lotion 790 was calendula oil.
  • Lotions 790 and 791 were identical except for the amounts of echium oil and calendula oil.
  • the six lotions were applied topically on EST 1000TM epidermis models (CellSystems Biotechnologiemaschinemaschine GmbH) in triplicates. One triplicate for each analysis was left untreated as control.
  • the models consist of primary human keratinocytes and exhibit a physiological differentiation pattern throughout the epidermal layers (as shown in Figure 1). These include a basal cell layer ⁇ stratum basale) spinous (or prickle) cell layer ⁇ stratum spinosum), granular layer ⁇ stratum granulosum) and finally the cornified layer ⁇ stratumcorneum) .
  • the cornified layer is responsible for the characteristic barrier capacity of the epidermis and is used as the main quality control for EST 1000TM. In this study EST 1000TM of 14 days of airlift culture were used.
  • RNAlater (Ambion) for R A preparation.
  • the RNA was prepared and the concentration and quality of the isolated RNA was controlled. The quality was determined by the ratio between the optical densities of the RNA at 260 and 280 nm. A ratio of more or equal 1.8 represents a good quality of RNA.
  • the gene expression of the Sirt 1 gene was analyzed by quantitative real time RT-PCR (Taqman) according to the Applied Biosystems protocol. In short: ⁇ g of the RNA was transcribed to cDNA which was used as a template for the real time RT-PCR with human sirt 1 specific primers and probes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composition comprenant (i) de l'acide stéaridonique, ou un ester de celui-ci, et éventuellement, (ii) un acide octadécatriénoïque conjugué ou un ester de celui-ci, destinée à être utilisée pour stimuler la synthèse de la sirtuine dans les cellules cutanées.
PCT/GB2011/051191 2010-06-24 2011-06-24 Composition pour le traitement de la peau Ceased WO2011161465A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1010638.3 2010-06-24
GBGB1010638.3A GB201010638D0 (en) 2010-06-24 2010-06-24 Composition for treatment of skin

Publications (2)

Publication Number Publication Date
WO2011161465A2 true WO2011161465A2 (fr) 2011-12-29
WO2011161465A3 WO2011161465A3 (fr) 2012-08-23

Family

ID=42582925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/051191 Ceased WO2011161465A2 (fr) 2010-06-24 2011-06-24 Composition pour le traitement de la peau

Country Status (2)

Country Link
GB (1) GB201010638D0 (fr)
WO (1) WO2011161465A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801900B2 (en) 2013-11-22 2017-10-31 Mary Kay Inc. Compositions for sensitive skin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046220A1 (fr) 1996-06-03 1997-12-11 Croda International Plc Compositions d'huile vegetale
WO2010089566A2 (fr) 2009-02-06 2010-08-12 Seeds Lp Composition destinée au traitement de la peau

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340485B1 (en) * 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
US20080213357A1 (en) * 2007-02-12 2008-09-04 Andrew Bruce Hebard Plant Derived Lipid Useful for Nutraceutical and Cosemeceutical Applications
GB0814105D0 (en) * 2008-08-01 2008-09-10 Springdale Sustainable Develop Composition for accelerated production of collagen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046220A1 (fr) 1996-06-03 1997-12-11 Croda International Plc Compositions d'huile vegetale
WO2010089566A2 (fr) 2009-02-06 2010-08-12 Seeds Lp Composition destinée au traitement de la peau

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAO,C. ET AL.: "SIRT 1 confers protection against UVB and H202 induced cell death via modulation of p53 and JNK in cultured skin keratinocytes", J CELL MOL MED, vol. 13, no. 9B, 2008, pages 3632 - 3643, XP009160306, DOI: doi:10.1111/j.1582-4934.2008.00453.x
MOREAU, M. ET AL.: "Enhancing cell longevity for cosmetic applications: a complimentary approach", J DRUGS DERMATOL, vol. 6, no. 6, June 2007 (2007-06-01), pages 14 - 19, XP002677889

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801900B2 (en) 2013-11-22 2017-10-31 Mary Kay Inc. Compositions for sensitive skin
US10245282B2 (en) 2013-11-22 2019-04-02 Mary Kay Inc. Compositions for sensitive skin
US10736837B2 (en) 2013-11-22 2020-08-11 Mary Kay Inc. Compositions for sensitive skin
US11559480B2 (en) 2013-11-22 2023-01-24 Mary Kay Inc. Compositions for sensitive skin
US11865204B2 (en) 2013-11-22 2024-01-09 Mary Kay Inc. Compositions for sensitive skin
US12233154B2 (en) 2013-11-22 2025-02-25 Mary Kay Inc Compositions for sensitive skin

Also Published As

Publication number Publication date
WO2011161465A3 (fr) 2012-08-23
GB201010638D0 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
Kensche et al. Lipids in preventive dentistry
KR101121949B1 (ko) 수분 함량을 높인 화장품 스팀 크림의 조성물 및 이의 제조방법
JP2020520371A (ja) バラエキスを含む化粧品組成物
US9403042B2 (en) Composition for treatment of skin
CN114129476A (zh) 包含植物果油和植物籽油的组合物及其应用
CN119792146A (zh) 包含植物种子油脂的组合物及其应用
Pavlačková et al. Stability and in vivo efficiency of natural cosmetic emulsion systems with the addition of vegetable oils
CN102238935B (zh) 将火绒草酸作为有效成分含有的改善皱纹用皮肤化妆料组合物
CN114146027B (zh) 包含微生物油脂和植物油脂的组合物及其应用
FR2935378A1 (fr) Utiisation de n-acyl aminoacides comme principes actifs cosmetiques et pharmaceutiques, capables de reduire l'etat inflammatoire des fibroblastes replicatifs senescents issus du derme humain adulte; compositions cosmetiques anti-age
EP3443949A1 (fr) Émulsion imitant la peau
El-Sheekh et al. Efficiency of the fatty acids extracted from the microalga Parachlorella kessleri in wound-healing
JP2005343882A (ja) ヒアルロン酸産生促進剤、アクアポリン合成促進剤、及び皮膚外用剤組成物
Manosroi et al. In vivo hair growth promotion activity of gel containing niosomes loaded with the Oryza sativa bran fraction (OSF3)
WO2011161465A2 (fr) Composition pour le traitement de la peau
KR101842752B1 (ko) 콜라겐과 히아루론산을 포함하는 천연 리포좀, 그 제조방법 및 이를 포함하는 화장료 조성물
CN111000789A (zh) 一种含omega-3抗衰活性物的化妆品组合物
EP3426355A1 (fr) Corps gras activé et/ou cire activée au moyen de la fraction non hydrosoluble du suc de carica papaya
Ismail et al. Anti-aging effect of mustard and flax seed oils based nanoemulsion gel on aged rat skin through antioxidant and anti-inflammatory activity
FR2988601A1 (fr) Utilisation des activateurs de hif1-alpha dans des compositions cosmetiques permettant d'effectuer un lipomodelage
JP6399545B2 (ja) 微細藻類由来の抗酸化剤およびこれを含有する化粧料又は皮膚外用剤
KR101993324B1 (ko) 피부 장벽 개선용 화장료 조성물
RU2170569C1 (ru) Крем косметический
Craveiro Skin-Friendly Oncosmetics–Specific Cosmetics for People Undergoing Cancer Treatment
JP2005206510A (ja) ヒアルロン酸産生促進剤及び皮膚外用剤組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11736440

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11736440

Country of ref document: EP

Kind code of ref document: A2